RARE Historical Earnings image   This RARE historical earnings page last updated 11/4/2022
RARE Historical Revenue
PeriodHistorical Earnings DateGAAP
Q3 202211/2/20220.09B
Q2 20227/28/20220.09B
Q1 20225/5/20220.08B
Q4 20212/10/20220.08B
Q3 202111/2/20210.08B
Q2 20218/2/20210.09B
Q1 20215/4/20210.10B
Q4 20202/11/20210.09B
Q3 202010/27/20200.08B
Q2 20207/30/20200.06B
Q1 20205/6/20200.04B
Q4 20192/13/20200.04B
Q3 201911/5/20190.03B
Q2 20198/1/20190.02B
Q1 20195/6/20190.02B
Q4 20182/19/201916.26M
Q3 201811/5/201811.76M
Q2 20188/2/201812.79M
Q1 20185/7/201810.68M
Q4 20172/20/20182.41M
Q3 201711/2/2017198000
Q2 20177/27/2017NA
Q1 20175/4/2017NA
Q4 20162/16/20175000
Q3 201611/7/2016111000
Q2 20168/8/201617000
Q1 20165/9/2016NA
Q4 20152/25/2016NA
Q3 201511/9/2015NA
Q2 20158/13/2015NA
Q1 20155/11/2015NA
Q4 20143/25/2015NA
Q3 201411/10/2014NA
Q2 20148/11/2014NA
Q1 20145/12/2014NA
RARE Historical Earnings EPS
PeriodHistorical Earnings DateAdj. EPS
Q3 202211/2/2022-2.430
Q2 20227/28/2022-2.260
Q1 20225/5/2022-2.190
Q4 20212/10/2022-1.790
Q3 202111/2/2021-1.080
Q2 20218/2/2021-1.810
Q1 20215/4/2021-2.030
Q4 20202/11/2021-0.370
Q3 202010/27/2020-1.130
Q2 20207/30/2020-1.120
Q1 20205/6/2020-2.050
Q4 20192/13/2020-1.620
Q3 201911/5/2019-1.960
Q2 20198/1/2019-1.720
Q1 20195/6/2019-1.820
Q4 20182/19/2019-1.73
Q3 201811/5/2018-1.74
Q2 20188/2/2018-1.87
Q1 20185/7/2018-2.03
Q4 20172/20/2018-1.52
Q3 201711/2/2017-1.87
Q2 20177/27/2017-1.72
Q1 20175/4/2017-1.63
Q4 20162/16/2017-1.75
Q3 201611/7/2016-1.64
Q2 20168/8/2016-1.46
Q1 20165/9/2016-1.35
Q4 20152/25/2016-1.42
Q3 201511/9/2015-1.03
Q2 20158/13/2015-0.83
Q1 20155/11/2015-0.63
Q4 20143/25/2015-0.52
Q3 201411/10/2014-0.5
Q2 20148/11/2014-0.45
Q1 20145/12/2014-0.85
Quotes delayed 20 minutes

Email EnvelopeFree RARE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Ultragenyx Pharmaceutical (RARE) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

RCEL Historical Earnings
RCKT Historical Earnings
RCUS Historical Earnings
RDNT Historical Earnings
RDUS Historical Earnings
REGN Historical Earnings
REPH Historical Earnings
REPL Historical Earnings
RETA Historical Earnings
RGEN Historical Earnings
What was the record high RARE historical earnings result?
In terms of earnings or revenue, what is the best RARE historical earnings result that Ultragenyx Pharmaceutical has ever posted, and when?

✔️Accepted answer: Within our data set, the highest RARE historical earnings result was set in Q4 2020, when Ultragenyx Pharmaceutical posted results of -0.370/share. The most successful revenue quarter within our data set was Q1 2021 when Ultragenyx Pharmaceutical reported revenue of 0.10B.

What was the lowest Ultragenyx Pharmaceutical historical earnings result?
In terms of top line revenue or bottom line earnings per share, what was the lowest RARE has reported, and when?

✔️Accepted answer: Within our data set, the lowest RARE historical earnings result was set in Q3 2022, when Ultragenyx Pharmaceutical posted results of -2.430/share. The smallest revenue quarter within our data set was Q2 2017 when Ultragenyx Pharmaceutical reported revenue of NA.

On this page we presented the RARE historical earnings date information for Ultragenyx Pharmaceutical. Reviewing that RARE Historical Earnings for the company, we see that the highest historical earnings result in our data set was in Q4 2020, when RARE posted adjusted EPS of -0.370/share. Meanwhile the lowest RARE historical earnings result was in Q3 2022, when RARE posted adjusted EPS of -2.430/share. Moving to Ultragenyx Pharmaceuticals historical revenue numbers, the largest revenue quarter in our data set was seen in Q1 2021 when RARE reported 0.10B in revenue, while the smallest revenue quarter was Q2 2017 when RARE reported NA in revenue.

For self directed investors doing their due diligence on RARE or any other given stock, their research can benefit from looking into all of the Ultragenyx Pharmaceutical historical earnings in our data set presented side by side on one page for ease of comparison. Reviewing this historical EPS information can help when projecting future earnings per share, as well as providing important context for pondering whether the historical earnings trajectory justifies the current stock value or not. That's why we bring you HistoricalEarnings.com to make it more convenient for investors to look into Ultragenyx Pharmaceutical historical earnings, or the historical earnings information for any stock in our coverage universe. In your continued due diligence investigations, we hope you check out the further links included for historical PE studies, earnings surprises history as well as next earnings dates for RARE. Thanks for visiting, and the next time you need to research RARE historical earnings or those of another stock, we hope our site will come to your mind as your preferred historical earnings, revenue, and EPS research resource of choice.

Recommended: FMIV YTD Return, Funds Holding BIND, Top Ten Hedge Funds Holding GDO.

 

RARE Historical Earnings | www.HistoricalEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.